Weronkia Buczek has been awarded a MRC DiMeN Doctoral Training Partnership for her PhD. The title of the project is ‘Molecular characterisation of the in vivo targets and mechanism of action of an acetylcholinesterase-derived peptide upregulated in Alzheimer’s disease.’
The academic lead for the project is Dr Mark Collins at the University of Sheffield and will be in partnership with us at Neuro-Bio.
As part of her PhD, Weronika will work with us for a number of months at the company with the objectives of: determining the mechanism for the generation and action of T14; characterising protein binding partners to identify new therapeutic targets and finally to help develop assays for T14 in CSF and plasma through the use of specialist techniques such as mass spectrometry.
We look forward to working with her!
The academic lead for the project is Dr Mark Collins at the University of Sheffield and will be in partnership with us at Neuro-Bio.
As part of her PhD, Weronika will work with us for a number of months at the company with the objectives of: determining the mechanism for the generation and action of T14; characterising protein binding partners to identify new therapeutic targets and finally to help develop assays for T14 in CSF and plasma through the use of specialist techniques such as mass spectrometry.
We look forward to working with her!